A retrospective, longitudinal, observational, multicenter study analysing retention rate and safety of Secukinumab in patients with ankylosing spondylitis and psoriatic arthritis in real clinical practice
Latest Information Update: 01 Jul 2020
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis; Spondylarthritis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 Jul 2020 New trial record
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism